That did cross my mind as well Funkeeh, being in a Ph3 but funded until Interim analysis by the FDA (being Orphan Disease, it is possible to gain priority review for Approval to market) & Unlisted option conversion for the rest of the trial funding.
DXB are quite regularly updating their Investor Presentation & getting the word out which is helpful to all of us, not just new investors.
I guess the DMX-700 pre-clinical results in COPD are very compelling though & hence I am keeping an open mind on moving forward with that IP ASAP.
Being also invested in IMU, who already had $100 mill in the bank & just raised another $80 million (a bit of a surprise to SH), it’s wise to never assume, especially when there are multiple irons in the fire with IP & we are still waiting on 2 external COVID-19 trial results here on DXB.
If they are positive results, well who knows? REMAP-CAP may extend DMX-200 plus ARB in trials, like they have with convalescent plasma in subgroups. New data on COVID coming out.
Recent data published by REMAP-CAP team:
https://link.springer.com/content/pdf/10.1007/s00134-022-06869-w.pdf
A lot of high risk patients for severe COVID (older, co-morbidity ie DKD, CKD, CVD) may already be on ARB, ACEi so would have excluded them (exclusion criteria) from recruitment onto the RAS Domain in REMAP-CAP & also I believe CLARITY trials, but not other Domains of REMAP-CAP.
Anyway, I also hope to hear some news soon, because if an oral treatment is beneficial, it could save a lot of heartbreak & a lot of health dollars being a global issue.
Anti-virals help, but not everyone tests positive quickly. I have had COVID-19 twice now, and obviously different “flavours” of the virus & 4 times positive cases in our household.
Symptoms were different between infections. & negative on RAT & PCR until day 5 or 6 of symptoms, so out of that window period for anti-virals anyway, & from what I’m hearing this isn’t uncommon, especially in vaccinated people. (Please not let’s go there again, it’s personal choice or mandatory for work & new strains are vaccine evasive for becoming infected, just may not get so sick & end up in hospital) so will be getting booster shots & just deal with it at the time. Twice being infected with COVID in 4 months is enough to deal with & I don’t want it again.
GLTAH
- Forums
- ASX - By Stock
- DXB
- Ann: Investor Presentation
Ann: Investor Presentation, page-20
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 0.395 |
7 | 153879 | 0.390 |
8 | 193916 | 0.385 |
9 | 349785 | 0.380 |
5 | 212000 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 33901 | 3 |
0.405 | 22128 | 1 |
0.410 | 125260 | 4 |
0.415 | 154602 | 6 |
0.420 | 119006 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |